TITLE

Percutaneous Closure of Left Atrial Appendage vs Warfarin Therapy

AUTHOR(S)
Karpman, Harold L.
PUB. DATE
October 2009
SOURCE
Internal Medicine Alert;10/15/2009, Vol. 31 Issue 19, p146
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The efficacy of percutaneous closure of the LAA with the WATCHMAN® left atrial closure device was found to be non-inferior to that of standard warfarin therapy for prevention of stroke, cardiovascular death, and/or systemic embolism and, therefore, the device might provide an alternative strategy to chronic warfarin therapy for stroke prophylaxis in patients with non-valvular atrial fibrillation.
ACCESSION #
44960610

 

Related Articles

  • PERCUTANEOUS CLOSURE OF LEFT ATRIAL APPENDAGE MAY DECREASE RISK OF DEATH AND HEMORRHAGIC STROKE COMPARED WITH WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION. Ehrlich, Alan // Clinical Advisor;Mar2015, Vol. 18 Issue 3, p76 

    No abstract available.

  • Left Atrial Appendage Occlusion vs Warfarin for Nonvalvular AF. Boyle, Andrew J. // Hospital Medicine Alert;May2013, Vol. 8 Issue 3, p22 

    The article discusses the effect of warfarin on left atrial appendage occlusion for nonvalvular atrial fibrillation (AF). It states that AF is a major source of morbidity. It also mentions that in presence of thromboembolism risk factors, AF is associated with an increased risk of stroke which...

  • Catheter-based left atrial appendage occlusion procedure: role of echocardiography. Perk, Gila; Biner, Simon; Kronzon, Itzhak; Saric, Muhamed; Chinitz, Larry; Thompson, Keith; Shiota, Takahiro; Hussani, Asma; Lang, Roberto; Siegel, Robert; Kar, Saibal // European Heart Journal - Cardiovascular Imaging;Feb2012, Vol. 13 Issue 2, p132 

    Atrial fibrillation is a common, clinically significant arrhythmic disorder that results in increased risk of morbidity and mortality in affected patients. Atrial fibrillation is more prevalent among men compared with women and the risk for developing atrial fibrillation increases with advancing...

  • Anticoagulation in Atrial Fibrillation. DiMarco, John P. // Clinical Cardiology Alert;Jun2007, Vol. 26 Issue 6, p46 

    ROWAN ET AL DESCRIBE RESULTS FROM THE National Ambulatory Medical Care Survey (NAMCS) Database with regard to the use of warfarin anticoagulation in patients with atrial fibrillation (AF). The NAMCS Database for the 1994 to 2003 time period contains data from 40.5 million AF patient visits....

  • Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. Van Gelder, Isabelle C.; Groenveld, Hessel F.; Crijns, Harry J. G. M.; Tuininga, Ype S.; Tijssen, Jan G. P.; Alings, A. Marco; Hillege, Hans L.; Bergsma-Kadijk, Johanna A.; Cornel, Jan H.; Kamp, Otto; Tukkie, Raymond; Bosker, Hans A.; Van Veldhuisen, Dirk J.; Van den Berg, Maarten P. // New England Journal of Medicine;4/15/2010, Vol. 362 Issue 15, p1363 

    Background: Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend strict rate control, but this is not based on clinical evidence. We hypothesized that lenient rate control is not inferior to strict rate control for preventing cardiovascular morbidity and...

  • Cardioembolic Stroke May Be Associated With Obstructive Sleep Apnea. Merriman, John // Pulmonary Reviews;Aug2012, Vol. 17 Issue 7, p1 

    The article discusses the commonality of cardioembolic stroke in patients with obstructive sleep apnea (OSA). Doctor Melissa C. Lipford and her colleagues at the Center for Sleep Medicine at the Mayo Clinic in Rochester, Minnesota examined the relationships between OSA, atrial fibrillation, and...

  • Apixaban reduced stroke or systemic embolism in AF more than warfarin regardless of type or duration of AF. Vasquez, Sara; Rondina, Matthew T. // Annals of Internal Medicine;7/16/2013, Vol. 159 Issue 2, pJC8 

    In this article, the author focus on the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study. According to the study, apixaban is more efficient than warfarin in AF patients and routine laboratory monitoring is essential in case of new oral...

  • Ximelagatran as effective as well-controlled warfarin.  // Formulary;Jan2004, Vol. 39 Issue 1, p42 

    Reveals results of clinical trials made on the cardiovascular drug called ximelagatran. Prevention of strokes and systemic embolic events in patients with nonvalvular atrial fibrillation; Comparison with warfarin; Rate of intracerebral hemorrhage.

  • New AF drug for GPs in Scotland.  // GP: General Practitioner;9/23/2011, p4 

    The article reports that Scottish Medicines Consortium (SMC) has approved dabigatran etexilate for the prevention of stroke and systemic embolism in adults with atrial fibrillation (AF). It mentions that general practitioners (GPs) now prescribe dabigatran etexilate to patients with AF in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics